La Jolla, CA, United States of America

Gisela-Andrea Camacho-Hernandez


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gisela-Andrea Camacho-Hernandez: Innovator in Nicotinic Receptor Research

Introduction

Gisela-Andrea Camacho-Hernandez is a prominent inventor based in La Jolla, California. She has made significant contributions to the field of pharmacology, particularly in the development of selective alpha-7 nicotinic receptor agonists. Her work focuses on creating compounds that can enhance cognitive function and memory retention.

Latest Patents

Gisela-Andrea holds a patent for "Selective alpha-7 nicotinic receptor agonists and methods for making and using them." This patent includes innovative agonists with high affinity for the alpha7 nicotinic acetylcholine receptor (α7 nAChR). The patent outlines various assays for assessing receptor selectivity and behavioral assessments aimed at reversing cognitive impairment. Additionally, it describes pharmaceutical compositions and formulations, as well as devices that incorporate these compounds.

Career Highlights

Gisela-Andrea is affiliated with the University of California, where she conducts her research. Her work has led to advancements in understanding the mechanisms of nicotinic receptors and their potential therapeutic applications. She has been recognized for her contributions to the field and continues to be an influential figure in pharmacological research.

Collaborations

Gisela-Andrea has collaborated with notable researchers such as Palmer Taylor and K. Barry Sharpless. These collaborations have further enriched her research and expanded the impact of her work in the scientific community.

Conclusion

Gisela-Andrea Camacho-Hernandez is a trailblazer in the field of nicotinic receptor research, with a focus on developing innovative therapeutic solutions. Her contributions are paving the way for advancements in cognitive enhancement and memory retention therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…